News & Events
Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress
Poster to highlight data on safety, tolerability, pharmacokinetics, and effects on hepcidin and measures of iron metabolism of DISC-0974 from phase 1 study in healthy volunteers WATERTOWN, Mass. (May 16, 2022) – Disc Medicine, a biotechnology company dedicated to the discovery and development of
More News
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg...
read more
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024 On track...
read more
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more